



ADAP1 promotes invasive squamous cell carcinoma progression and predicts patient survival

Avery Van Duzer, Sachiko Taniguchi, Ajit Elhance, Takahiro Tsujikawa, and Naoki Oshimori

DOI: 10.26508/lsa.201900582

Corresponding author(s): Dr. Naoki Oshimori (Knight Cancer Institute, Oregon Health & Science University)

Review timeline:

Submission Date:	2019-10-22
Editorial Decision:	2019-10-23
Revision Received:	2019-10-29
Editorial Decision:	2019-10-31
Revision Received:	2019-11-04
Accepted:	2019-11-05

Scientific Editor: Andrea Leibfried

Transaction Report:

(Note: With the exception of the correction of typographical or spelling errors that could be a source of ambiguity, letters and reports are not edited. The original formatting of letters and referee reports may not be reflected in this compilation.)

No Peer Review Process File is available with this article, as the authors have chosen not to make the review process public in this case.



1st Editorial Decision

23 October 2019

October 23, 2019

Re: Life Science Alliance manuscript #LSA-2019-00582-T

Dr. Naoki Oshimori
Department of Cell, Developmental & Cancer Biology
Knight Cancer Institute
Oregon Health & Science University
2720 SW Moody Ave
KCRB 3002
Portland, OR 97201, USA

Dear Dr. Oshimori,

Thank you for transferring your manuscript entitled "Tumor-initiating cells trigger basement membrane breakdown via ADAP1 to promote invasive tumor progression" to Life Science Alliance. The manuscript was assessed by expert reviewers at another journal before, and the editors transferred those reports to us with your permission.

The reviewers appreciated the proposed role of ADAP1 for tumor invasiveness, but thought that its role in breakdown of the basement membrane was not sufficiently supported and that the interplay with Arf6 would need better insight. We think that a revised version concentrating on ADAP1 as a predictor of survival and on its role in migration in conjunction with Arf6 would be suitable for publication in Life Science Alliance, and we would thus like to invite you to submit a revised version to us. Importantly, we would expect a full point-by-point response to the reviewer concerns. Please provide better experimental support for the proposed link to Arf6 regulation underlying the observed phenotype and remove the part suggesting alterations of integrin / BM downstream of this. The requested controls, side-by-side comparison, number of patients (rev#3), and clarifications should get provided and ADAP1 effects in SCCs should get tested (rev#1 and #2).

To upload the revised version of your manuscript, please log in to your account: <https://lsa.msubmit.net/cgi-bin/main.plex>
You will be guided to complete the submission of your revised manuscript and to fill in all necessary information. Please get in touch in case you do not know or remember your login name.



While you are revising your manuscript, please also attend to the below editorial points to help expedite the publication of your manuscript. Please direct any editorial questions to the journal office.

Thank you for this interesting contribution to Life Science Alliance. We are looking forward to receiving your revised manuscript.

Sincerely,

Andrea Leibfried, PhD
Executive Editor
Life Science Alliance
Meyershofstr. 1
69117 Heidelberg, Germany
t +49 6221 8891 502
e a.leibfried@life-science-alliance.org
www.life-science-alliance.org

A. THESE ITEMS ARE REQUIRED FOR REVISIONS

- A letter addressing the reviewers' comments point by point.
- An editable version of the final text (.DOC or .DOCX) is needed for copyediting (no PDFs).
- High-resolution figure, supplementary figure and video files uploaded as individual files: See our detailed guidelines for preparing your production-ready images, <http://www.life-science-alliance.org/authors>
- Summary blurb (enter in submission system): A short text summarizing in a single sentence the study (max. 200 characters including spaces). This text is used in conjunction with the titles of papers, hence should be informative and complementary to the title and running title. It should describe the context and significance of the findings for a general readership; it should be written in the present tense and refer to the work in the third person. Author names should not be mentioned.

B. MANUSCRIPT ORGANIZATION AND FORMATTING:

Full guidelines are available on our Instructions for Authors page, <http://www.life-science-alliance.org/authors>

We encourage our authors to provide original source data, particularly uncropped/-processed electrophoretic blots and spreadsheets for the main figures of the manuscript. If you would like to add source data, we would welcome one PDF/Excel-file per figure for this information. These files will be linked online as supplementary "Source Data" files.

*****IMPORTANT:** It is Life Science Alliance policy that if requested, original data images must be made available. Failure to provide original images upon request will result in unavoidable delays in publication. Please ensure that you have access to all original microscopy and blot data images before submitting your revision.***



October 31, 2019

RE: Life Science Alliance Manuscript #LSA-2019-00582-TR

Dr. Naoki Oshimori
Knight Cancer Institute, Oregon Health & Science University
Cell, Developmental & Cancer Biology
2720 SW Moody Ave
Portland, OR 97201

Dear Dr. Oshimori,

Thank you for submitting your revised manuscript entitled "ADAP1 promotes invasive squamous cell carcinoma progression and predicts patient survival". I now assessed the revised version of your manuscript and appreciate the changes introduced and the experiments added, including those added to better link ADAP1-mediated effects to Arf6 mis-regulation. I would thus be happy to publish your paper in Life Science Alliance pending final revisions necessary to meet our formatting guidelines:

- please state in the figure legends next to the p-values which statistical test has been employed
- you mention an RNA-seq experiment for figure 5E, please correct (I assume the results refer to RT-PCR analysis as indicated in the M&M section)

If you are planning a press release on your work, please inform us immediately to allow informing our production team and scheduling a release date.

To upload the final version of your manuscript, please log in to your account:

<https://lsa.msubmit.net/cgi-bin/main.plex>

You will be guided to complete the submission of your revised manuscript and to fill in all necessary information. Please get in touch in case you do not know or remember your login name.

To avoid unnecessary delays in the acceptance and publication of your paper, please read the following information carefully.

A. FINAL FILES:

These items are required for acceptance.

-- An editable version of the final text (.DOC or .DOCX) is needed for copyediting (no PDFs).

-- High-resolution figure, supplementary figure and video files uploaded as individual files: See our detailed guidelines for preparing your production-ready images, <http://www.life-science-alliance.org/authors>

-- Summary blurb (enter in submission system): A short text summarizing in a single sentence the study (max. 200 characters including spaces). This text is used in conjunction with the titles of papers, hence should be informative and complementary to the title. It should describe the context and significance of the findings for a general readership; it should be written in the present tense and refer to the work in the third person. Author names should not be mentioned.



B. MANUSCRIPT ORGANIZATION AND FORMATTING:

Full guidelines are available on our Instructions for Authors page, <http://www.life-science-alliance.org/authors>

We encourage our authors to provide original source data, particularly uncropped/-processed electrophoretic blots and spreadsheets for the main figures of the manuscript. If you would like to add source data, we would welcome one PDF/Excel-file per figure for this information. These files will be linked online as supplementary "Source Data" files.

****Submission of a paper that does not conform to Life Science Alliance guidelines will delay the acceptance of your manuscript.****

****It is Life Science Alliance policy that if requested, original data images must be made available to the editors. Failure to provide original images upon request will result in unavoidable delays in publication. Please ensure that you have access to all original data images prior to final submission.****

****The license to publish form must be signed before your manuscript can be sent to production. A link to the electronic license to publish form will be sent to the corresponding author only. Please take a moment to check your funder requirements.****

****Reviews, decision letters, and point-by-point responses associated with peer-review at Life Science Alliance will be published online, alongside the manuscript. If you do want to opt out of having the reviewer reports and your point-by-point responses displayed, please let us know immediately.****

Thank you for your attention to these final processing requirements. Please revise and format the manuscript and upload materials within 7 days.

Thank you for this interesting contribution, we look forward to publishing your paper in Life Science Alliance.

Sincerely,

Andrea Leibfried, PhD
Executive Editor
Life Science Alliance
Meyershofstr. 1
69117 Heidelberg, Germany
t +49 6221 8891 502
e a.leibfried@life-science-alliance.org
www.life-science-alliance.org



3rd Editorial Decision

5 November 2019

November 5, 2019

RE: Life Science Alliance Manuscript #LSA-2019-00582-TRR

Dr. Naoki Oshimori
Knight Cancer Institute, Oregon Health & Science University
Cell, Developmental & Cancer Biology
2720 SW Moody Ave
Portland, OR 97201

Dear Dr. Oshimori,

Thank you for submitting your Research Article entitled "ADAP1 promotes invasive squamous cell carcinoma progression and predicts patient survival". It is a pleasure to let you know that your manuscript is now accepted for publication in Life Science Alliance. Congratulations on this interesting work.

The final published version of your manuscript will be deposited by us to PubMed Central upon online publication.

Your manuscript will now progress through copyediting and proofing. It is journal policy that authors provide original data upon request.

Reviews, decision letters, and point-by-point responses associated with peer-review at Life Science Alliance will be published online, alongside the manuscript. If you do want to opt out of having the reviewer reports and your point-by-point responses displayed, please let us know immediately.

IMPORTANT: If you will be unreachable at any time, please provide us with the email address of an alternate author. Failure to respond to routine queries may lead to unavoidable delays in publication.

Scheduling details will be available from our production department. You will receive proofs shortly before the publication date. Only essential corrections can be made at the proof stage so if there are any minor final changes you wish to make to the manuscript, please let the journal office know now.

DISTRIBUTION OF MATERIALS:

Authors are required to distribute freely any materials used in experiments published in Life Science Alliance. Authors are encouraged to deposit materials used in their studies to the appropriate repositories for distribution to researchers.

You can contact the journal office with any questions, contact@life-science-alliance.org

Again, congratulations on a very nice paper. I hope you found the review process to be constructive and are pleased with how the manuscript was handled editorially. We look forward to future exciting submissions from your lab.

Sincerely,

Andrea Leibfried, PhD



Executive Editor
Life Science Alliance
Meyerhofstr. 1
69117 Heidelberg, Germany
t +49 6221 8891 502
e a.leibfried@life-science-alliance.org
www.life-science-alliance.org